2026年辉瑞历年年报/社会责任报告/ESG报告合集（共44套打包）

1、gPfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceFocused Execution Drives Strong Full-Year 2025 EPS PerformanceEnters 2026 with Clear Strategic Priorities and Growing Late-Stag。

2、1Fourth Quarter 2025Earnings TeleconferenceFebruary 3,2026Fourth Quarter 2025 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentFourth Quarter 2025 Earning。

3、REFINITIV STREETEVENTSEDITED TRANSCRIPTPFE.N-Q3 2025 Pfizer Inc Earnings CallEVENT DATE/TIME:NOVEMBER 04,2025/3:00PM GMTOVERVIEW:Company SummaryREFINITIV STREETEVENTS|Contact Us2025 Refinitiv.All ri。

4、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended Septe。

5、1Third Quarter 2025Earnings TeleconferenceNovember4,2025Third Quarter 2025 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentThird Quarter 2025 Earnings3 O。

6、gPfizer Reports Solid Third-Quarter 2025 Results;Raises and Narrows 2025 EPS GuidanceFocused Execution Delivers Strong EPS Performance Landmark Agreement Reached with U.S.Government Provides。

7、gPfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS GuidanceStrengthened Commercial Execution Driving Topline GrowthContinued Progress Across R&D PipelineExpanded Programs On T。

8、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 。

9、REFINITIV STREETEVENTSEDITED TRANSCRIPTPFE.N-Q2 2025 Pfizer Inc Earnings CallEVENT DATE/TIME:AUGUST 05,2025/2:00PM GMTOVERVIEW:Company SummaryREFINITIV STREETEVENTS|Contact Us2025 Refinitiv.All righ。

10、1Second Quarter 2025Earnings TeleconferenceAugust5,2025Second Quarter 2025 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentSecond Quarter 2025 Earnings3 。

11、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March。

12、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

13、gPfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 GuidanceDelivers Robust Earnings Performance,Successfully Navigating a Dynamic EnvironmentMade Significant Progress Strengthening t。

14、REFINITIV STREETEVENTSEDITED TRANSCRIPTPFE.N-Q1 2025 Pfizer Inc Earnings CallEVENT DATE/TIME:APRIL 29,2025/2:00PM GMTOVERVIEW:Company SummaryREFINITIV STREETEVENTS|Contact Us2025 Refinitiv.All right。

15、1First Quarter 2025Earnings TeleconferenceApril29,2025First Quarter 2025 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentFirst Quarter 2025 Earnings3Our 。

16、Breakthroughs that change patients lives July 30,2024Second Quarter 2024 Earnings TeleconferenceIntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice President3Second Quarter 20。

17、1Third Quarter 2024Earnings TeleconferenceOctober29,2024Third Quarter 2024 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentThird Quarter 2024 Earnings3Ou。

18、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

19、Breakthroughs that change patients lives May 1,2024First Quarter 2024 Earnings TeleconferenceIntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice President3First Quarter 2024 E。

20、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

21、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended April。

22、2021年，我们为获得监管机构批准的新药物或适应症患者开辟了新领域，为世界各地的人群提供了拯救生命的COVID-19疫苗，并推出了可能改变游戏规则的COVID-19口服治疗方法。2021年对辉瑞来说是分水岭的一年。。

23、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K(Mark One)ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended Dec。

24、花旗银行慢性腰痛慢性骨髓性白血病开发市场、西欧、日本、加拿大、澳大利亚、韩国、斯堪的纳维亚国家、芬兰和新西兰欧洲经济区基本健康执行领导团队欧洲药品管理局新兴市场包括但不限于以下市场:亚洲(不包括日本和韩国)、拉丁美洲、东欧、非洲、中东、中欧和土耳其一般公认会计原则生长激素不足胃肠道间质瘤全球产品开发组织高盛，萨克斯公司。。

25、Appendix A2018 Financial Report?!?#?$?%?$?&!?!?#$?$?%?&?(?$?%?$?(?)?*?$?*?!?$?$?$?%?+?,?!?$?$?-?%?.?$?/?%?.?0?!?12?$?$?-?%?.?0?!?12?$?$?-?%?.?0?$?%?%?3?!?#?$?%?(4(?$?0?$?%?0?$?$?%?5?$?/$?0?&a。

26、Pfizer Inc.2009 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary CompaniesIntroductionOur Financial Review is provided to assist readers in understanding the results of operations,financial 。

27、Appendix A2016 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary Companies2016 Financial Report iGLOSSARY OF DEFINED TERMSUnless the context requires otherwise,references to“Pfizer,”“the Comp。

28、Appendix A2015 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary Companies2015 Financial Report 1INTRODUCTIONOur Financial Review is provided to assist readers in understanding the results of。

29、Appendix A2014 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary Companies2014 Financial Report 1INTRODUCTIONOur Financial Review is provided to assist readers in understanding the results of。

30、Appendix A2013 Financial ReportAppendixA.indd 13/1/13 4:13 PMFinancial ReviewPfizer Inc.and Subsidiary Companies2013 Financial Report 1INTRODUCTIONOur Financial Review is provided to assist readers i。

31、Appendix A2012 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary Companies2012 Financial Report 1INTRODUCTIONOur Financial Review is provided to assist readers in understanding the results of。

32、Appendix A2011 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary CompaniesINTRODUCTIONOur Financial Review is provided to assist readers in understanding the results of operations,financial c。

33、Appendix A2010 Financial ReportFinancial ReviewPfizer Inc.and Subsidiary CompaniesIntroductionOur Financial Review is provided to assist readers in understanding the results of operations,financial c。

34、AnnuAl Review 2009SCIENCEWe bring the best scientific minds together to challenge the most feared diseases of our timeJean Cui(center)and her la Jolla laboratories team are pioneering new approaches 。

35、2023Impact ReportPfizer 2023 Impact Report2IntroductionGovernanceSocialEnvironmentAppendixESG PerformanceIntroductionGovernanceSocialEnvironmentAppendixESG PerformanceWhere to find more information20。

36、DOINg THINgS DIffERENTlyaNNual REVIEw ARE BECOMING THE PFIZER WE ARE MEANT TO BE ONE THAT CAN OFFER HEALTHY SOLUTIONS AT EVERY STAGE OF LIFEIn Pfizers ongoing transformation,we are challenging the co。

37、Environmental,Social&Governance ReportPfizer 2022Pfizer 2022 ESG Report2In This ReportIntroductionA Letter from our Chairman&CEOA Letter from Our Lead Independent Director2022 Progress and Hi。

38、Pfizer Inc.2007 Financial Report2007 Financial ReportFinancial Review.1Managements Report on Internal Control Over Financial Reporting .36Audit Committees Report .36Report of Independent Registered P。

39、Pfizer Inc.2006 Financial ReportThis Page Intentionally Left BlankIntroductionOur Financial Review is provided in addition to the accompanyingconsolidated financial statements and footnotes to assist。

40、回顾过去的一年，我对我们的科学突破持续为患者和社会带来的积极影响感到非常自豪。通过继续专注于我们的目标，我们能够在帮助应对世界上一些最紧迫的挑战方面取得前所未有的进展。我还意识到，我们还有很多事情要做，我们必须克服严重的不平等现象，我们的社会和环境面临着切实的威胁。。

41、Appendix A2008 Financial ReportTHIS PAGE INTENTIONALLY LEFT BLANKFinancial ReviewPfizer Inc and Subsidiary CompaniesIntroductionOur Financial Review is provided in addition to the accompanying consol。